Our Mission
The National Bleeding Disorders Foundation (NBDF) Hawaii Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing complications of these disorders through research, education, and advocacy enabling people and families to thrive.
Our Mission ... In Action
-
Giving you education & support for you and your family is our top priority. Our programs will help you connect with others, give you important information on care, and gain support.
-
We fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
-
We provide year-round events and fundraisers to spread awareness, educate and generate crucial resources in support of our mission. We hope to see you at our next event!
News Articles
Keri Norris, PhD, JM, MPH, MCHES, Senior Vice President, Health Access and Strategic Innovation, of the National Bleeding Disorders Foundation is a Fierce DEI Award Finalist in the Leadership in Health Equity Category
Dr. Norris has been recognized for her transformative work advancing health access in the inheritable blood and bleeding disorders community.
Because May is Mental Health Awareness Month, the Neil Frick Resource Center (NFRC) is dedicating its most recent Resource Round Up (formerly HANDI Highlights) to supporting mental well-being. This edition approaches this vital topic from a variety of perspectives, with information delivered through multiple formats, including videos, articles, referral resources, and podcasts.
Through investment and partnership, Pathway to Cures encourages early-stage biotech companies to develop treatments that have the potential to improve the lives of people in our community.
Since Pathway to Cures (P2C) launched in 2023, more than 200 early-stage biotechnology, pharma, medical device and diagnostic companies, with innovative approaches that address unmet needs in our blood and bleeding disorders community, have been reviewed by our team.
Bayer recently announced that the company’s hemophilia A therapy Jivi® has been granted an expanded indication from the U.S. Food and Drug Administration (FDA). Jivi is a long-acting site-specifically PEGylated recombinant factor VIII therapy that was first FDA-approved in 2018 for use in previously treated individuals with hemophilia A, including adolescents and adults 12 years of age and over. This indication encompassed prophylactic, on-demand, and perioperative management of bleeding.
